IP Library › Granted Patent US 12,728,160
Granted Patent B2
US 12,728,160 · App. 18/017,371 · Granted Sep 8, 2026

Vaccine using M2/BM2-deficient influenza vectors

Inventors: Michael J. Moser (Madison, WI); David J. Marshall (Madison, WI); Liam I. Marshall (Madison, WI); Yasuko Hatta (Madison, WI); Pamuk Bilsel (Madison, WI)
Assignee: FluGen, Inc.
A61K39/215C07K14/11A61K2039/543A61K2039/70C12N2770/20022
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,728,160
App. No.
18/017,371
Granted
Sep 8, 2026
Kind
B2
Abstract

The invention provides a recombinant virus comprising an influenza viral backbone, wherein the influenza viral backbone comprises PB1, PB2, PA, NP, M, NS, HA, and NA gene segments, wherein at least one of the PB1, PB2, PA, NP, M, NS, HA, and NA gene segments comprises at least one nucleotide sequence that encodes one or more antigens. The invention provides a recombinant virus wherein the antigen is an immunogenic fragment of SARS-CoV-2 spike glycoprotein. The invention also provides a pharmaceutical formulation and a method of eliciting an immune response.

Claims (29)

1 . A recombinant virus comprising an influenza viral backbone, wherein the influenza viral backbone comprises PB1, PB2, PA, NP, M, NS, HA, and NA gene segments, wherein at least one of the PB1, PB2, PA, NP, M, NS, HA, and NA gene segments comprises at least one nucleotide sequence that encodes one or more antigens, and wherein

(a) the PB1 gene segment encodes a PB1 protein having an amino acid sequence comprising selected amino acids, wherein the selected amino acids comprise a leucine at position 40 and a tryptophan at position 180, and at least one of an asparagine at position 464, an isoleucine at position 563, or a serine at position 607, and wherein the PB1 gene segment optionally comprises a cytosine to uracil promoter mutation at nucleotide position 4;

(b) the PB2 gene segment encodes a PB2 protein having an amino acid sequence comprising selected amino acids, wherein the selected amino acids comprise a valine at position 504, and optionally an isoleucine at position 467 and a valine at position 529, and wherein the PB2 gene segment optionally comprises a cytosine to uracil promoter mutation at nucleotide position 4;

(c) the PA gene segment encodes a PA protein having an amino acid sequence comprising selected amino acids, wherein the selected amino acids comprise a lysine at position 401, and wherein the PA gene segment optionally comprises a cytosine to uracil promoter mutation at nucleotide position 4;

(d) the NP gene segment encodes an NP protein having an amino acid sequence comprising selected amino acids, wherein the selected amino acids comprise a leucine at position 116, and at least one of a lysine at position 294 or an arginine at position 311; and

(e) the NS gene segment encodes an NS1 protein having amino acid sequence comprising selected amino acids, wherein the selected amino acids comprise a proline at position 30, a lysine at position 55, and a lysine at position 118.

2 . The recombinant virus of claim 1 , wherein the antigen is an immunogenic fragment of SARS-CoV-2 spike glycoprotein.

3 . The recombinant virus of claim 1 , wherein the M gene segment comprises at least one nucleotide sequence that encodes an antigen, wherein the antigen is an immunogenic fragment of SARS-CoV-2 spike glycoprotein.

4 . The recombinant virus of claim 1 , wherein the M gene segment encodes a mutated M2 protein.

5 . The recombinant virus of claim 4 , wherein the M gene segment encodes a protein comprising at least one linker protein and FLAG epitope tag.

6 . The recombinant virus of claim 1 , wherein the M segment encodes a protein comprising any one of SEQ ID NOs: 1-14 and 92-96.

7 . The recombinant virus of claim 1 , wherein the NS gene segment comprises at least one nucleotide sequence that encodes one or more antigens.

8 . The recombinant virus of claim 1 wherein the antigen is an immunogenic fragment of SARS-CoV-2 spike glycoprotein.

9 . The recombinant virus of claim 1 , wherein the NS gene segment encodes (1) a NS1 protein, (2) at least one flexible linker protein, (3) an immunogenic fragment of SARS-CoV-2 spike glycoprotein, (4) at least one cleavable cleavage sequence, and (5) a NEP protein.

10 . The recombinant virus of claim 9 , wherein the at least one cleavable cleavage sequence is a T2A peptide sequence or a P2A peptide sequence.

11 . The recombinant virus of claim 1 , wherein the NS gene segment encodes a protein comprising any one of SEQ ID NOs: 97-104.

12 . The recombinant virus of claim 1 , wherein each of the M and NS gene segments comprises at least one nucleotide sequence that encodes one or more antigens, and wherein the antigens are immunogenic fragments of SARS-CoV-2 spike glycoprotein.

13 . The recombinant virus of claim 1 , wherein each of the NA and NS gene segments comprises at least one nucleotide sequence that encodes one or more antigens, and wherein the antigens are immunogenic fragments of SARS-CoV-2 glycoprotein.

14 . The recombinant virus of claim 1 , wherein each of the M and NA gene segments comprises at least one nucleotide sequence that encodes one or more antigens, and wherein the antigens are immunogenic fragments of SARS-CoV-2 glycoprotein.

15 . The recombinant virus of claim 1 , wherein each of the M and HA gene segments comprises at least one nucleotide sequence that encodes one or more antigens, and wherein the antigens are immunogenic fragments of SARS-CoV-2 glycoprotein.

16 . The recombinant virus of claim 1 , wherein each of the NS and NA gene segments comprises at least one nucleotide sequence that encodes one or more antigens, and wherein the antigens are immunogenic fragments of SARS-CoV-2 glycoprotein.

17 . The recombinant virus of claim 1 , wherein each of the NS and HA gene segments comprises at least one nucleotide sequence that encodes one or more antigens, and wherein the antigens are immunogenic fragments of SARS-CoV-2 spike glycoprotein.

18 . The recombinant virus of claim 1 , wherein the virus is capable of replication in human cells.

19 . The recombinant virus of claim 1 , wherein the virus has enhanced growth as compared to a recombinant virus that is the same except without the selected amino acids in Vero cells under the same conditions.

20 . The recombinant virus of claim 1 , wherein the gene segment that comprises at least one nucleotide sequence that encodes one or more antigens further comprises a downstream duplication and wherein the downstream duplication comprises at least one silent nucleotide mutation.

21 . A pharmaceutical formulation comprising the recombinant virus of claim 1 .

22 . The pharmaceutical formulation of claim 21 , wherein the vaccine is formulated as a monovalent vaccine, a bivalent vaccine, a trivalent vaccine, or a quadrivalent vaccine.

23 . A method of eliciting an immune response in a mammal, the method comprising administering the recombinant virus of claim 1 to the mammal, thereby eliciting an immune response to the antigen in the mammal.

24 . The method of claim 23 , wherein the mammal is a human.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 26, 2024
From: MOSER, MICHAEL J.; MARSHALL, DAVID J.; MARSHALL, LIAM I.; HATTA, YASUKO; BILSEL, PAMUK
To: FLUGEN, INC.
Reel/Frame 067240/0808 →
Continuity (2)
Provisional Application 63054700 · Jul 21, 2020
Related Publication 20230256086A1 · Aug 17, 2023
References Cited (150)
US 6270958B1 · Olivo et al. · 2001 [cited by applicant]
US 6544785B1 · Palese et al. · 2003 [cited by applicant]
US 6872395B2 · Kawaoka · 2005 [cited by applicant]
US 7176021B2 · Kawaoka · 2007 [cited by applicant]
US 7226774B2 · Kawaoka · 2007 [cited by applicant]
US 7276356B1 · Palese et al. · 2007 [cited by applicant]
US 7312064B2 · Hoffmann · 2007 [cited by applicant]
US 7384774B2 · Palese et al. · 2008 [cited by applicant]
US 7459162B2 · Yang et al. · 2008 [cited by applicant]
US 7510719B2 · Dang et al. · 2009 [cited by applicant]
US 7566458B2 · Yang et al. · 2009 [cited by applicant]
US 7585657B2 · Kawaoka · 2009 [cited by applicant]
US 7588769B2 · Kawaoka · 2009 [cited by applicant]
US 7723094B2 · Kawaoka et al. · 2010 [cited by applicant]
US 7790434B2 · Duke et al. · 2010 [cited by applicant]
US 7959930B2 · De Wit et al. · 2011 [cited by applicant]
US 7968101B2 · Kawaoka et al. · 2011 [cited by applicant]
US 7972843B2 · Hoffmann · 2011 [cited by applicant]
US 7993924B2 · Billeter et al. · 2011 [cited by applicant]
US 8012736B2 · Hoffman et al. · 2011 [cited by applicant]
US 8012737B2 · Dang et al. · 2011 [cited by applicant]
US 8043856B2 · Kawaoka et al. · 2011 [cited by applicant]
US 8048430B2 · Yang et al. · 2011 [cited by applicant]
US 8057806B2 · Kawaoka · 2011 [cited by applicant]
US 8163523B2 · Bilsel et al. · 2012 [cited by applicant]
US 8202726B2 · Liu et al. · 2012 [cited by applicant]
US 8288145B2 · Röthl et al. · 2012 [cited by applicant]
US 8298805B2 · Kawaoka · 2012 [cited by applicant]
US 8333975B2 · Yang et al. · 2012 [cited by applicant]
US 8404248B2 · Yang et al. · 2013 [cited by applicant]
US 8465960B2 · Kawaoka et al. · 2013 [cited by applicant]
US 8475806B2 · Kawaoka et al. · 2013 [cited by applicant]
US 8507247B2 · Kawaoka et al. · 2013 [cited by applicant]
US 8574593B2 · Yang et al. · 2013 [cited by applicant]
US 8592196B2 · Kittel et al. · 2013 [cited by applicant]
US 8597661B2 · Kawaoka et al. · 2013 [cited by applicant]
US 8673613B2 · Jin et al. · 2014 [cited by applicant]
US 8679819B2 · Kawaoka · 2014 [cited by applicant]
US 8685410B2 · Yang et al. · 2014 [cited by applicant]
US 8691239B2 · Yang et al. · 2014 [cited by applicant]
US 8715940B2 · Kawaoka et al. · 2014 [cited by applicant]
US 8859208B2 · Kawaoka et al. · 2014 [cited by applicant]
US 8877209B2 · Kawaoka et al. · 2014 [cited by applicant]
US 8877210B2 · Yang et al. · 2014 [cited by applicant]
US 8877448B2 · Kawaoka et al. · 2014 [cited by applicant]
US 8883479B2 · Krenn et al. · 2014 [cited by applicant]
US 9023603B2 · Kawaoka et al. · 2015 [cited by applicant]
US 9068986B2 · Jin et al. · 2015 [cited by applicant]
US 9085753B2 · Liu et al. · 2015 [cited by applicant]
US 9101653B2 · Kawaoka et al. · 2015 [cited by applicant]
US 9109013B2 · Kawaoka et al. · 2015 [cited by applicant]
US 9119810B2 · Montelione et al. · 2015 [cited by applicant]
US 9157096B2 · Kawaoka et al. · 2015 [cited by applicant]
US 9254318B2 · Kawaoka et al. · 2016 [cited by applicant]
US 9284533B2 · Bilsel et al. · 2016 [cited by applicant]
US 9474798B2 · Watanabe et al. · 2016 [cited by applicant]
US 9580693B2 · Kawaoka et al. · 2017 [cited by applicant]
US 9732313B2 · Hirschel et al. · 2017 [cited by applicant]
US 9757446B2 · LeFebvre et al. · 2017 [cited by applicant]
US 9890363B2 · Kawaoka et al. · 2018 [cited by applicant]
US 9919042B2 · Bilsel et al. · 2018 [cited by applicant]
US 9919043B2 · Bilsel et al. · 2018 [cited by applicant]
US 9926535B2 · Kawaoka et al. · 2018 [cited by applicant]
US 9950057B2 · Kawaoka et al. · 2018 [cited by applicant]
US 10022434B2 · Weiner et al. · 2018 [cited by applicant]
US 10053671B2 · Kawaoka et al. · 2018 [cited by applicant]
US 10059925B2 · Kawaoka et al. · 2018 [cited by applicant]
US 10119124B2 · Watanabe et al. · 2018 [cited by applicant]
US 10130697B2 · Watanabe et al. · 2018 [cited by applicant]
US 10172934B2 · Kawaoka et al. · 2019 [cited by applicant]
US 10246686B2 · Kawaoka et al. · 2019 [cited by applicant]
US 10358630B2 · Kawaoka et al. · 2019 [cited by applicant]
US 10494613B2 · Kawaoka et al. · 2019 [cited by applicant]
US 10500267B2 · LeFebvre et al. · 2019 [cited by applicant]
US 10513692B2 · Kawaoka et al. · 2019 [cited by applicant]
US 10570376B2 · Peterka et al. · 2020 [cited by applicant]
US 10633422B2 · Kawaoka et al. · 2020 [cited by applicant]
US 10808229B2 · Kawaoka et al. · 2020 [cited by applicant]
US 11007262B2 · Watanabe et al. · 2021 [cited by applicant]
US 11046934B2 · Kawaoka et al. · 2021 [cited by applicant]
US 11180737B2 · Kawaoka et al. · 2021 [cited by applicant]
US 11197925B2 · Kawaoka et al. · 2021 [cited by applicant]
US 20030035814A1 · Kawaoka et al. · 2003 [cited by applicant]
US 20040180058A1 · Shneider et al. · 2004 [cited by applicant]
US 20090246830A1 · Kawaoka et al. · 2009 [cited by applicant]
US 20110300604A1 · Kawaoka et al. · 2011 [cited by applicant]
US 20130115242A1 · Moules et al. · 2013 [cited by applicant]
US 20130243804A1 · Stoloff et al. · 2013 [cited by applicant]
US 20150017205A1 · Kawaoka et al. · 2015 [cited by applicant]
US 20150166967A1 · Kawaoka et al. · 2015 [cited by applicant]
US 20150368621A1 · Kawaoka et al. · 2015 [cited by applicant]
US 20160002606A1 · Peterka et al. · 2016 [cited by applicant]
US 20160284020A1 · Williams · 2016 [cited by applicant]
US 20170198264A1 · Kawaoka et al. · 2017 [cited by applicant]
US 20170216425A1 · Ahmed et al. · 2017 [cited by applicant]
US 20170258888A1 · Kawaoka et al. · 2017 [cited by applicant]
US 20170354730A1 · Kawaoka et al. · 2017 [cited by applicant]
US 20180340152A1 · Kawaoka et al. · 2018 [cited by applicant]
US 20190048324A1 · Kawaoka et al. · 2019 [cited by applicant]
US 20190060441A1 · Bilsel et al. · 2019 [cited by applicant]
US 20190167781A1 · Kawaoka et al. · 2019 [cited by applicant]
US 20190184007A1 · Ahmed et al. · 2019 [cited by applicant]
US 20200061182A1 · Bilsel et al. · 2020 [cited by applicant]
US 20200188506A1 · Kawaoka et al. · 2020 [cited by applicant]
US 20200263143A1 · Kawaoka et al. · 2020 [cited by applicant]
US 20220241397A1 · Hatta et al. · 2022 [cited by applicant]
US 20230295582A1 · Moser et al. · 2023 [cited by applicant]
CN 102864127A · 2013 [cited by applicant]
CN 102864128A · 2013 [cited by applicant]
CN 102864129A · 2013 [cited by applicant]
WO 2005115448A2 · 2005 [cited by applicant]
WO 2006083286A2 · 2006 [cited by applicant]
WO WO2010117786A1 · 2010 [cited by applicant]
WO 2011014504A1 · 2011 [cited by applicant]
WO 2015063085A1 · 2015 [cited by applicant]
WO 2015142671A2 · 2015 [cited by applicant]
WO WO2017007839A1 · 2017 [cited by applicant]
WO 2017184626A1 · 2017 [cited by applicant]
WO WO2018157028A1 · 2018 [cited by applicant]
WO WO2018157047A1 · 2018 [cited by applicant]
WO WO2022020460A1 · 2022 [cited by applicant]
WO WO2022020469A1 · 2022 [cited by applicant]
Furusawa et al., “Influenza Virus Polymerase Mutation Stabilizes a Foreign Gene Inserted into the Virus Genome by Enhancing the Transcription/Replication Efficiency of the Modified Segment,” mBio 10(5): e01794-19 (2019). [cited by applicant]
Heaton et al., “In Vivo Bioluminescent Imaging of Influenza A Virus Infection and Characterization of Novel Cross-Protective Monoclonal Antibodies,” Journal of Virology, 87(15): 8272-8281 (2013). [cited by applicant]
Hoffmann et al., “Universal primer set for the full-length amplification of all influenza A viruses,” Arch. Virol., 146: 2275-2289 (2001). [cited by applicant]
Jin et al., “Multiple amino acid residues confer temperature sensitivity to human influenza virus vaccine strains (FluMist) derived from cold-adapted A/Ann Arbor/6/60,” Virology, 306: 18-24 (2003). [cited by applicant]
Manicassamy et al., “Analysis of in vivo dynamics of influenza virus infection in mice using a GFP reporter virus,” PNAS, 107(25): 11531-11536 (2010). [cited by applicant]
Nogales et al., “A Novel Fluorescent and Bioluminescent Bireporter Influenza A Virus to Evaluate Viral Infections,” Journal of Virology, 93(10): e00032-19 (2019). [cited by applicant]
Pan et al., “Development and application of bioluminescence imaging for the influenza A virus,” J. Thorac. Dis., 10 (Suppl. 19): S2230-S2237 (2018). [cited by applicant]
Wang et al., “Generation of a Reassortant Influenza A Subtype H3N2 Virus Expressing Gaussia Luciferase,” Viruses, 11(7): 665 (2019). [cited by applicant]
European Patent Office, Extended European Search Report in European Patent Application No. 21845261.3 (Sep. 30, 2024). [cited by applicant]
European Patent Office, Extended European Search Report in European Patent Application No. 21845413.0 (Oct. 14, 2024). [cited by applicant]
Japan Patent Office, Notice of Reasons for Refusal in Japanese Patent Application No. 504319-2023 (Jul. 29, 2025). [cited by applicant]
Globaldata Healthcare, “Influenza vaccine: FluGen has successful Phase II trial for M2SR,” Feb. 22. 2019, XP093027811, Retrieved from the Internet Mar. 1, 2023 https://www.pharmaceutical-technology.com/comment/flugen-su… [cited by applicant]
Hatta et al., “M2SR, a novel live influenza vaccine, protects mice and ferrets against highly pathogenic avian influenza,” [cited by applicant]
Hu et al., “A Vero-cell-adapted vaccine donor strain of influenza A virus generated by serial passages,” [cited by applicant]
European Patent Office, Extended European Search Report in European Patent Application No. 20 818 294.9 (Mar. 13, 2023). [cited by applicant]
Clark, et al.,“Functional Evolution of Influenza Virus NS1 Protein in Currently Circulating Human 2009 Pandemic H1N1 Viruses,” [cited by applicant]
Davis et al., “Identification of influenza A nucleoprotein body domain residues essential for viral RNA expression expose antiviral target,” [cited by applicant]
Liedmann et al., “Viral suppressors of the RIG-I-mediated interferon responses are pre-packaged in influenza virions,” [cited by applicant]
Ping et al., “Development of high-yield influenza A virus vaccine viruses,” [cited by applicant]
U.S. Patent and Trademark Office, International Search Report for International Patent Application PCT/US2020/036455 (Sep. 30, 2020). [cited by applicant]
U.S. Patent and Trademark Office, International Search Report in International Patent Application No. PCT/US2021/042561 (Dec. 21, 2021). [cited by applicant]
U.S. Patent and Trademark Office, Written Opinion in International Patent Application No. PCT/US2021/042561 (Dec. 21, 2021). [cited by applicant]
U.S. Patent and Trademark Office, International Search Report in International Patent Application No. PCT/US2021/042572 (Nov. 10, 2021). [cited by applicant]
U.S. Patent and Trademark Office, Written Opinion in International Patent Application No. PCT/US2021/042572 (Nov. 10, 2021). [cited by applicant]
Uniprot, Identification No. A0A0M3Z509_9INFA, NP.5 (Jun. 5, 2019) [retrieved from the internet URL https://www.uniprot.org/uniprot/A0A0M3Z509.txt?version=21> on Sep. 2, 2020]. [cited by applicant]
Uniprot, Identification No. A0A0M5HQ96_9INFA, PB1.5 (Jun. 5, 2019) [retrieved from the internet URL https://www.uniprot.org/uniprot/A0A0M5HQ96.txt?version=20> on Sep. 2, 2020]. [cited by applicant]
Watanabe et al., “Influenza A Virus Lacking M2 Protein as a Live Attenuated Vaccine,” [cited by applicant]
Yamaji et al., “Mammalian Adaptive Mutations of the PA Protein of Highly Pathogenic Avian H5N1 Influenza Virus,” [cited by applicant]